Pregnancy & Neuromuscular Disease

Neuromuscular disorders present unique challenges during pregnancy, labor, and the postpartum period. Physiologic changes of pregnancy — including increased blood volume, weight gain, elevated progesterone levels, and immunologic shifts from Th1 to Th2 predominance — can unmask or exacerbate underlying neuromuscular conditions. Management requires a multidisciplinary approach involving neurologists, maternal-fetal medicine specialists, anesthesiologists, and neonatologists. Preconception counseling, medication optimization, and planned delivery are cornerstones of safe outcomes for both mother and infant.

Myasthenia Gravis in Pregnancy

Disease Course & Exacerbation Risk

Myasthenia gravis is the most commonly encountered neuromuscular disorder in pregnancy, with peak incidence overlapping the reproductive years. Approximately 30–40% of pregnant women with MG experience exacerbation, most frequently during the first trimester or within the first month postpartum. The postpartum period is particularly vulnerable due to immune reconstitution and the stress of labor and sleep deprivation. However, recent registry data demonstrate that planned pregnancies — with stable disease on optimized therapy for ≥6 months prior to conception — are associated with significantly reduced rates of exacerbation, hospitalization, and ICU admission.

Neonatal Myasthenia & Fetal Complications

Transient neonatal myasthenia gravis affects 10–20% of infants born to mothers with MG, caused by transplacental transfer of maternal AChR antibodies. Symptoms include weak cry, poor feeding, hypotonia, and respiratory insufficiency, typically appearing within the first 48 hours and resolving spontaneously over 2–4 weeks as maternal antibodies are cleared. Notably, there is no reliable correlation between maternal disease severity or antibody titers and the occurrence of neonatal MG. In rare cases, maternal antibodies targeting fetal AChR subunits can cause fetal arthrogryposis multiplex congenita — a severe condition with fixed joint contractures detectable on prenatal ultrasound.

Treatment of MG Exacerbations in Pregnancy

Myasthenic crisis during pregnancy requires urgent treatment. Intravenous immunoglobulin (IVIg) at 2 g/kg over 5 days is the preferred first-line rescue therapy given its established safety profile in pregnancy. Plasma exchange (PLEX) is equally effective and safe but carries practical challenges including vascular access and hemodynamic shifts. Dose adjustments of pyridostigmine may be needed due to altered gastrointestinal motility and increased renal clearance during pregnancy.

Myotonic Dystrophy

Myotonic dystrophy type 1 (DM1) is the most common adult-onset muscular dystrophy and poses substantial maternal and fetal risks during pregnancy. Registry-based studies report a 32.5% miscarriage rate, with common complications including preterm labor (27.8%), pre-eclampsia (10.4%), and peripartum hemorrhage (13.9%). Uterine smooth muscle myotonia can cause dysfunctional labor patterns, prolonged labor, and uterine atony with postpartum hemorrhage.

Guillain-Barré Syndrome in Pregnancy

The incidence of GBS during pregnancy is approximately 1.2–1.9 per 100,000 — similar to the general population. GBS can occur at any stage of gestation but is more common in the third trimester and early postpartum period. The immunologic shift back toward Th1 predominance after delivery may trigger or exacerbate the autoimmune process. Treatment follows standard protocols: IVIg (0.4 g/kg/day for 5 days) is preferred over PLEX due to its favorable safety profile and ease of administration. Full recovery occurs in 70–80% of patients with prompt immunomodulation. GBS does not affect uterine smooth muscle, so vaginal delivery remains feasible in the absence of severe respiratory or motor compromise.

CIDP in Pregnancy

Chronic inflammatory demyelinating polyradiculoneuropathy may relapse during pregnancy, particularly in the third trimester and postpartum period, when immune shifts favor autoimmunity. Relapse rates of 25–50% have been reported during pregnancy or within the first 3 months after delivery. IVIg is the preferred maintenance therapy during pregnancy, avoiding the fetal risks associated with prolonged corticosteroid use (gestational diabetes, adrenal suppression, premature rupture of membranes). PLEX is an alternative for refractory cases. Disease-modifying agents such as mycophenolate and rituximab should be discontinued before conception.

Muscular Dystrophies

Female carriers of dystrophinopathies (Duchenne and Becker muscular dystrophy) may be manifesting carriers with subclinical or overt skeletal muscle weakness and, importantly, cardiomyopathy. Approximately 8–17% of DMD carriers develop dilated cardiomyopathy, which may decompensate under the hemodynamic stress of pregnancy. All DMD/BMD carriers should undergo cardiac evaluation with echocardiography and consideration of cardiac MRI before and during pregnancy. Manifesting carriers are also at risk for respiratory insufficiency, and baseline pulmonary function testing is essential.

Spinal Muscular Atrophy

Women with SMA types 2 and 3 can achieve successful pregnancies with careful multidisciplinary planning. However, 31–42% experience disease exacerbation during pregnancy, including progressive weakness and respiratory decline. Restrictive lung disease is the primary concern: the growing uterus further compromises already limited diaphragmatic excursion, and respiratory failure may necessitate noninvasive ventilation or even intubation. As of 2024, nusinersen continuation during pregnancy is permitted following a favorable opinion from the European Medicines Agency. Early case reports demonstrate maintained motor function and no adverse fetal effects with intrathecal nusinersen during the third trimester. Cesarean delivery is frequently required due to pelvic and skeletal deformities and limited expulsive effort.

Medication Safety in Pregnancy & Breastfeeding

Labor & Delivery Considerations

Planning for delivery should begin early in pregnancy, with a written anesthesia plan reviewed by the multidisciplinary team. The mode of delivery (vaginal vs. cesarean) depends on the specific neuromuscular condition, severity of weakness, respiratory reserve, and obstetric indications. Neuromuscular disease alone is not an indication for cesarean section — the uterus, being smooth muscle, is unaffected by most neuromuscular conditions (except myotonic dystrophy).

Breastfeeding

Most first-line neuromuscular medications are compatible with breastfeeding. Pyridostigmine, low-dose corticosteroids, azathioprine, and IVIg have minimal transfer into breast milk and pose negligible risk to the nursing infant. Rituximab concentrations in breast milk are 200–300 times lower than maternal serum, and breastfeeding is considered acceptable. Mycophenolate, methotrexate, and cyclophosphamide are contraindicated during lactation. For newer agents (eculizumab, efgartigimod, nusinersen), data remain limited but their large molecular size or intrathecal route of administration suggests minimal milk transfer. The decision to breastfeed must also weigh the physical demands of nursing — fatigue and sleep disruption may exacerbate myasthenia or other neuromuscular conditions in the postpartum period.

References

1. Norwood F, et al. Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry. 2014;85(5):538–543.
2. Anabusi S, et al. Pregnancy planning may impact maternal and neonatal outcomes in people with myasthenia gravis. Muscle Nerve. 2024;69(3):331–337.
3. Gveric-Ahmetasevic S, et al. Treatment considerations in myasthenia gravis for the pregnant patient. Expert Rev Neurother. 2023;23(4):345–357.
4. Hoff JM, et al. Myasthenia gravis: consequences for pregnancy, delivery, and the newborn. Neurology. 2003;61(10):1362–1366.
5. Batocchi AP, et al. Course and treatment of myasthenia gravis during pregnancy. Neurology. 1999;52(3):447–452.
6. Lake AJ, et al. Severe preeclampsia in the setting of myasthenia gravis. Case Rep Obstet Gynecol. 2017;2017:9204930.
7. Nguyen-Khoa BA, et al. Management of myasthenia gravis during pregnancy. Ther Adv Neurol Disord. 2019;12:1756286419833713.
8. Johnson NE, et al. The impact of pregnancy on myotonic dystrophy: a registry-based study. J Neuromuscul Dis. 2015;2(4):447–452.
9. Campbell C, Bhatt T. Pregnancy and childbirth in women with myotonic dystrophy type 1. Obstet Gynecol. 2019;133(3):579–585.
10. Rudnik-Schöneborn S, et al. Pregnancy and delivery in myotonic dystrophy type 2. Neurology. 2006;66(2):270–272.
11. Chan LY, et al. Guillain-Barré syndrome in pregnancy. Acta Obstet Gynecol Scand. 2004;83(4):319–325.
12. Vijayaraghavan J, et al. Guillain-Barré syndrome in pregnancy: a case report and review of the literature. Obstet Gynecol Surv. 2024;79(4):232–240.
13. McCombe PA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy associated with pregnancy. Ann Neurol. 1987;21(1):102–104.
14. Querol L, et al. EAN/PNS guideline on diagnosis and treatment of CIDP: second revision. J Peripher Nerv Syst. 2021;26(3):242–268.
15. Politano L, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 1996;6(Suppl 1):S31–S34.
16. Awater C, et al. Pregnancy in patients with inherited neuromuscular disorders. Eur J Obstet Gynecol Reprod Biol. 2012;162(2):153–159.
17. Abati E, et al. Pregnancy outcomes in women with spinal muscular atrophy: a review. J Neurol Sci. 2018;388:50–54.
18. Florianska A, et al. The first patient in Poland treated for SMA with nusinersen during pregnancy. J Clin Med. 2024;13(23):7366.
19. Trevisan CP, et al. Pregnancy in a patient with spinal muscular atrophy and severe restrictive lung disease. Neurol Sci. 2024;45(2):797–800.
20. Godoy DA, et al. Maternal health and obstetric complications of genetic neuromuscular disorders in pregnancy: a systematic review. Neuromuscul Disord. 2024;44:103698.